The Blizard Institute (Neuroscience, Surgery & Trauma), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK; Department of Neurology, Hospital General Universitario de Castellón, Castellón de la Plana, Spain.
The Blizard Institute (Neuroscience, Surgery & Trauma), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK; Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Mult Scler Relat Disord. 2020 Aug;43:102140. doi: 10.1016/j.msard.2020.102140. Epub 2020 Apr 28.
To report three cases of severe skin reactions in patients treated with cladribine for multiple sclerosis.
Case study.
Patients developed severe rash 3-192 days after receiving cladribine. All were effectively treated with steroids and antihistamines. Additional doses of cladribine were administered after pretreatment with steroids and anti-histamines. One patient developed mild recurrence following re-exposure, which resolved within three days, whilst another patient tolerated re-exposure without further adverse reaction.
Severe skin reactions, well described in patients receiving cladribine for treatment of haematological conditions, may occur in patients treated with this compound for multiple sclerosis. Neurologists need to be aware of this rare, but significant adverse reaction. Re-exposure may be safe with standard pre-treatment against allergic reactions.
报告 3 例接受克拉屈滨治疗多发性硬化症的患者发生严重皮肤反应的病例。
病例研究。
患者在接受克拉屈滨治疗后 3-192 天出现严重皮疹。所有患者均经类固醇和抗组胺药物有效治疗。在类固醇和抗组胺药物预处理后给予克拉屈滨的额外剂量。1 例患者在再次接触后出现轻度复发，3 天内消退，另 1 例患者再次接触后无不良反应。
在接受克拉屈滨治疗血液疾病的患者中已有严重皮肤反应的详细描述，在接受该药物治疗多发性硬化症的患者中也可能发生。神经科医生需要意识到这种罕见但严重的不良反应。标准的过敏反应预处理后再次接触可能是安全的。
